| Application no. and date | 21207246.6 (espacenet) (Federated) (European Patent Register), 20170519 | | Patent/reg. no. and date | DK/EP 4019019, 20240207 | | Publication date | 20220629 | | Priority no. and date | US 201662339433 P, 20160520 | | EP pub. no. and date |
EP 4019019 20220629 | | Effective date | | | Applicant/owner | Biohaven Therapeutics Ltd., 215 Church Street
New Haven, CT 06510, US | | Applicant ref. no. | PU281514DKQ | | Inventor | CORIC, Vladimir,
New Haven, 06520, US | | Representative | Marks & Clerk LLP, 44 rue de la Vallée
BP 1775
L-1017 Luxembourg, LU | | Opponent | | | IPC Class | A61K 31/428 (2006.01) , A61P 35/00 (2006.01) , C07D 277/82 (2006.01) | | Title | ANVENDELSE AF RILUZOL, RILUZOLPRODRUGS ELLER RILUZOLANALOGER MED
IMMUNTERAPIER TIL CANCERBEHANDLING | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
